Statin Intolerant? What to Do Instead (2026 Update)

Why It Matters

The updated guidelines give physicians actionable alternatives to statins, ensuring LDL targets are met while minimizing muscle toxicity, which broadens treatment options for a growing population of statin‑intolerant patients.

Key Takeaways

• Statin-fibrate combo discontinued; diet and fish oil recommended.
• Prescription EPA (4g) cuts cardiovascular events 25% versus OTC fish oil.
• Bempedoic acid offers LDL reduction with minimal muscle side effects.
• Baseline CK testing before statins debated for active exercisers.
• 2026 guidelines prioritize non‑statin agents to achieve LDL goals.

Summary

The video tackles statin intolerance, outlining the 2026 clinical update on how to manage patients who cannot tolerate traditional statin‑fibrate therapy. It follows a case study of a man whose statin‑induced myositis prompted a shift to a health‑promoting diet, fish‑oil supplementation, and continuation of a lower‑dose statin without fibrate. Key insights include abandoning the statin‑fibrate combo, leveraging prescription‑grade EPA (4 g daily) that cut cardiovascular events by 25 % versus over‑the‑counter fish oil, and adding non‑statin agents such as bempedoic acid, ezetimibe, or PCSK9 inhibitors to hit LDL targets. The discussion also covers measuring LP(a) and the contentious idea of obtaining baseline CK levels in athletes before starting statins. Notable details feature the patient’s CK and transaminases normalizing within a month, triglycerides dropping modestly, and the mechanistic advantage of bempedoic acid as a liver‑activated pro‑drug that spares muscle tissue. The hosts debate whether routine CK checks are practical, noting CK fluctuations with exercise akin to hormone variability. The implications are clear: clinicians now have a broader therapeutic arsenal to achieve LDL goals without sacrificing muscle health, and patients can remain on statins or switch to alternatives while maintaining exercise regimens. Personalized monitoring and adherence to the updated guidelines can reduce cardiovascular risk and improve overall outcomes.

Original Description

If you develop a real statin intolerance, that’s not the end of the road. The 2026 ACC lipid guidelines provide a clear escalation pathway, and there are more options now than ever. In this segment, we cover what happened to our patient after discharge, the role of prescription omega-3s vs. over-the-counter fish oil, how bempedoic acid works without affecting muscle, and why you should ask your doctor about Lp(a).

We also discuss Jordan’s proposal for baseline CK testing in exercisers before starting a statin, and close with direct advice for anyone on a statin who trains.

Timestamps

0:00 — What happened to the patient

0:23 — Fish oil: OTC vs. prescription omega-3s (REDUCE-IT data)

2:02 — Patient follow-up: labs, exercise, and quitting smoking

2:27 — 2026 guidelines escalation: bempedoic acid, PCSK9i, inclisiran

3:04 — Bempedoic acid: the prodrug that skips muscle

3:44 — Lp(a): the test you should get once

4:19 — Should we get baseline CK in exercisers?

5:54 — Advice for patients and lifters

Full article: https://www.barbellmedicine.com/blog/statins-muscle-strength/

Next Steps

Check out our new book, Signal (coming soon)

For evidence-based resistance training programs: barbellmedicine.com/training-programs

For individualized training consultation: barbellmedicine.com/coaching

Explore our full library of articles on health and performance: barbellmedicine.com/resources

To consult with Drs. Baraki or Feigenbaum email us at [e-mail]

To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com

Resources:

Blumenthal RS, et al. 2026 ACC/AHA Dyslipidemia Guideline. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423

Bhatt DL, et al. REDUCE-IT. NEJM. 2019;380:11–22. https://pubmed.ncbi.nlm.nih.gov/30415628/

Lee YJ, et al. Ez-PAVE: Intensive LDL Targeting. NEJM. 2026. PMID: 41910315